Marc Alan Pfeffer, M.D., Ph.D.
This page shows the publications co-authored by Marc Pfeffer and Ebrahim Barkoudah.
Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. 2012 Feb; 1(1):8-15.
Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT. J Card Fail. 2022 May 28.
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 11 11; 385(20):1845-1855.
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 Mar 28; 368(13):1210-9.
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circ Heart Fail. 2021 12; 14(12):e008597.
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2021 05; 9(5):374-382.
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC Heart Fail. 2021 01; 9(1):13-24.
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 10 24; 381(17):1609-1620.
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009 Aug; 11(8):795-801.
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10; 370(15):1383-92.
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010 Aug 10; 122(6):597-602.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.